DK0670162T3 - Farmaceutiske formuleringer indeholdende raloxifen, et overfladeaktivt middel og et vandopløseligt fortyndingsmiddel - Google Patents

Farmaceutiske formuleringer indeholdende raloxifen, et overfladeaktivt middel og et vandopløseligt fortyndingsmiddel

Info

Publication number
DK0670162T3
DK0670162T3 DK95301291T DK95301291T DK0670162T3 DK 0670162 T3 DK0670162 T3 DK 0670162T3 DK 95301291 T DK95301291 T DK 95301291T DK 95301291 T DK95301291 T DK 95301291T DK 0670162 T3 DK0670162 T3 DK 0670162T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical formulations
surfactant
water
formulations containing
soluble diluent
Prior art date
Application number
DK95301291T
Other languages
Danish (da)
English (en)
Inventor
Arvind Lavji Thakkar
Stephanie Ann Sweetana
Lowell Lee Gibson
Kerry John Hartauer
Julian Larry Stowers
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0670162T3 publication Critical patent/DK0670162T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK95301291T 1994-03-02 1995-02-28 Farmaceutiske formuleringer indeholdende raloxifen, et overfladeaktivt middel og et vandopløseligt fortyndingsmiddel DK0670162T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20491594A 1994-03-02 1994-03-02
SG1997000220A SG65636A1 (en) 1994-03-02 1997-01-30 Orally administrable pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DK0670162T3 true DK0670162T3 (da) 2002-03-11

Family

ID=26665140

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95301291T DK0670162T3 (da) 1994-03-02 1995-02-28 Farmaceutiske formuleringer indeholdende raloxifen, et overfladeaktivt middel og et vandopløseligt fortyndingsmiddel

Country Status (22)

Country Link
EP (1) EP0670162B1 (fi)
JP (1) JP3574210B2 (fi)
CN (1) CN1098684C (fi)
AT (1) ATE211910T1 (fi)
AU (1) AU684882B2 (fi)
BR (1) BR9500758A (fi)
CA (1) CA2143263C (fi)
CZ (1) CZ286119B6 (fi)
DE (1) DE69524981T2 (fi)
DK (1) DK0670162T3 (fi)
ES (1) ES2166799T3 (fi)
FI (1) FI117042B (fi)
HU (1) HU225418B1 (fi)
IL (1) IL112746A (fi)
NO (1) NO314286B1 (fi)
NZ (1) NZ270588A (fi)
PL (1) PL178858B1 (fi)
PT (1) PT670162E (fi)
RU (1) RU2118540C1 (fi)
SG (1) SG65636A1 (fi)
SI (1) SI0670162T1 (fi)
ZA (1) ZA951497B (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
EP2266560A1 (en) * 1996-03-26 2010-12-29 Eli Lilly & Company Benzothiophenes, formulations containing same, and methods
CA2219377A1 (en) * 1996-10-30 1998-04-30 Eli Lilly And Company Improvements in or relating to the prophylaxis of breast cancer
ZA992858B (en) 1996-10-30 1999-07-29 Lilly Co Eli Methods of preventing breast cancer.
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
JP4798924B2 (ja) * 1999-12-13 2011-10-19 中外製薬株式会社 ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物
AU780947B2 (en) * 1999-12-13 2005-04-28 Chugai Seiyaku Kabushiki Kaisha Compound having hydroxycarbonyl-halogenoalkyl side chain
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
KR100861466B1 (ko) * 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 항혈관형성제 및 ＴＮＦα를 이용한 병용 요법
AU2003266940B2 (en) 2002-09-30 2007-02-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US20050008704A1 (en) * 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
WO2008000042A1 (en) 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
EP2197423B1 (en) * 2007-10-16 2014-12-03 Pharmathen S.A. Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
EP2242483B1 (en) * 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
NZ595986A (en) 2009-04-24 2014-04-30 Iceutica Pty Ltd A novel formulation of indomethacin
WO2011000581A2 (en) 2009-07-02 2011-01-06 Synthon B.V. Raloxifene composition
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
DK2925320T3 (da) 2012-11-30 2021-05-10 Pharmathen Sa Hidtil ukendt fremgangsmåde til forbedring af bio-tilgængeligheden af lægemidler med lav vandopløselighed
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
KR102612983B1 (ko) * 2016-09-30 2023-12-13 한미약품 주식회사 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
NO950799L (no) 1995-09-04
CA2143263A1 (en) 1995-09-03
SG65636A1 (en) 1999-06-22
EP0670162A1 (en) 1995-09-06
DE69524981T2 (de) 2002-08-29
AU684882B2 (en) 1998-01-08
ATE211910T1 (de) 2002-02-15
NZ270588A (en) 1996-01-26
CZ49995A3 (en) 1995-10-18
HU9500635D0 (en) 1995-04-28
JP3574210B2 (ja) 2004-10-06
CZ286119B6 (cs) 2000-01-12
EP0670162B1 (en) 2002-01-16
SI0670162T1 (en) 2002-06-30
BR9500758A (pt) 1995-10-24
AU1354895A (en) 1995-09-07
IL112746A (en) 1999-12-31
FI950947A (fi) 1995-09-03
IL112746A0 (en) 1995-05-26
FI117042B (fi) 2006-05-31
PL178858B1 (pl) 2000-06-30
CN1112420A (zh) 1995-11-29
FI950947A0 (fi) 1995-03-01
ZA951497B (en) 1996-08-23
HU225418B1 (en) 2006-11-28
NO950799D0 (no) 1995-03-01
PT670162E (pt) 2002-06-28
DE69524981D1 (de) 2002-02-21
CA2143263C (en) 2002-01-08
JPH07277973A (ja) 1995-10-24
PL307491A1 (en) 1995-09-04
CN1098684C (zh) 2003-01-15
HUT72661A (en) 1996-05-28
ES2166799T3 (es) 2002-05-01
NO314286B1 (no) 2003-03-03
RU2118540C1 (ru) 1998-09-10

Similar Documents

Publication Publication Date Title
DK0670162T3 (da) Farmaceutiske formuleringer indeholdende raloxifen, et overfladeaktivt middel og et vandopløseligt fortyndingsmiddel
DK0698393T3 (da) 3-/-menthoxypropan-1,2-diol som solubiliseringsmiddel og præparat til udvortes brug, der indeholder samme
DK0948965T3 (da) Stabile medicinske præparater indeholdende 4,5-epoxymorphinanderivater
ES2052809T3 (es) Agente desinfectante tuberculocida.
DK159856C (da) Humaninsulinderivater og farmaceutiske praeparater, som indeholder disse derivater
NO902280L (no) Ny poroes farmasoeytisk form og fremstilling derav.
MA23136A1 (fr) Composition de nettoyage comprenant des tensio- actifs a courte chaine .
NO913035D0 (no) (2r)-2-(di(2-propyl)fosfonylmetoksy)-3-p-toluensulfonyloksy-1-trimetylacetoksypropan, fremgangsmaate for fremstilling og anvendelse derav.
NO902277L (no) Baere- eller foeringsvalse og anordning som anvender slike.
ES2129108T3 (es) Procedimiento para una preparacion estabilizadora para lentes de contacto.
NO900564L (no) Overflateaktivt middel.
NO901169D0 (no) Azol-1-alkanamider som anti-arrytmiske midler og fremstilling derav.
ATE149360T1 (de) Zahnseide mit chemotherapeutischen wirkstoffen
MY117590A (en) Orally administerable pharmaceutical formulations
NO901200L (no) Azol-1-alkanamider som anti-arrytmiske midler og fremstilling derav.
IT8922281A0 (it) Composizioni e metodo per la disinfezione e la pulizia delle lenti a contatto rigide, semirigide e morbide.
KR940023572U (ko) 이동식 진공튀져(tweezer)